BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration. 1999

D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Clinical Pharmacokinetic Laboratory, Haut-Lévêque Hospital, University of Bordeaux II, Bordeaux, Lyon, France.

The objective of this study was to analyze the pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration. Six patients received 15 mg of isepamicin per kg of body weight. The mean isepamicin concentration peak in serum was 62.88 +/- 18.20 mg/liter 0.5 h after the infusion. The elimination half-life was 7. 91 +/- 0.83 h. The mean total body clearance was 1.75 +/- 0.28 liters/h, and dialysate outlet (DO) clearance was 2.76 +/- 0.59 liters/h. The mean volume of distribution was 19.83 +/- 2.95 liters. The elimination half-life, DO clearance, and volume of distribution were almost constant. In this group of patients, the initial dosage of 15 mg/kg appeared to be adequate, but the dosage interval should be determined by monitoring residual isepamicin concentrations in plasma.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001499 Bayes Theorem A theorem in probability theory named for Thomas Bayes (1702-1761). In epidemiology, it is used to obtain the probability of disease in a group of people with some characteristic on the basis of the overall rate of that disease and of the likelihood of that characteristic in healthy and diseased individuals. The most familiar application is in clinical decision analysis where it is used for estimating the probability of a particular diagnosis given the appearance of some symptoms or test result. Bayesian Analysis,Bayesian Estimation,Bayesian Forecast,Bayesian Method,Bayesian Prediction,Analysis, Bayesian,Bayesian Approach,Approach, Bayesian,Approachs, Bayesian,Bayesian Approachs,Estimation, Bayesian,Forecast, Bayesian,Method, Bayesian,Prediction, Bayesian,Theorem, Bayes

Related Publications

D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
A pilot study of netilmicin pharmacokinetics during continuous venovenous hemodiafiltration.
April 2005, Journal of clinical pharmacology,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
February 2002, Pharmacotherapy,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients.
January 2014, Antimicrobial agents and chemotherapy,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration.
July 2021, Open forum infectious diseases,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration.
October 2010, The Annals of pharmacotherapy,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.
December 2003, Journal of clinical pharmacology,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Cyclosporine and vancomycin disposition during continuous venovenous hemodiafiltration.
April 1995, The Annals of pharmacotherapy,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Pharmacokinetics of meprobamate in overdose treated with continuous venovenous hemodiafiltration (CVVHDF).
October 2013, Hemodialysis international. International Symposium on Home Hemodialysis,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Pharmacokinetics of Peramivir in an Adolescent Patient Receiving Continuous Venovenous Hemodiafiltration.
January 2017, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
D Breilh, and B Allaouchiche, and H Jaumain, and P Boulétreau, and D Chassard, and I Malbec, and D Ducint, and M C Saux
Ceftaroline Pharmacokinetics in a Critically Ill Adult Receiving Continuous Venovenous Hemodiafiltration.
August 2022, The Annals of pharmacotherapy,
Copied contents to your clipboard!